Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.

Modular Medical, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, CA / ACCESS NEWSWIRE / DECEMBER 31, 2025 / MODULAR MEDICAL, INC. (NASDAQ:MODD) ("MODULAR MEDICAL" OR THE "COMPANY"), AN INSULIN DELIVERY TECHNOLOGY COMPANY WITH THE FIRST FDA-CLEARED PATCH PUMP DESIGNED SPECIFICALLY TO TARGET ALL ADULT "ALMOST-PUMPERS" WITH ITS USER-FRIENDLY AND AFFORDABLE DESIGN, TODAY ANNOUNCED THE COMPANY RECEIVED WRITTEN NOTIFICATION FROM THE LISTING QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET LLC ("NASDAQ"), GRANTING THE COMPANY'S REQUEST FOR A 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT UNDER NASDAQ LISTING RULE 5810(C)(3)(A) (THE "BID PRICE RULE"). THE COMPANY NOW HAS UNTIL JUNE 29, 2026 TO MEET THE REQUIREMENT.

MODULAR MEDICAL RECEIVES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE RULE

SAN DIEGO, CA / ACCESS NEWSWIRE / DECEMBER 10, 2025 / MODULAR MEDICAL, INC. (NASDAQ:MODD) ("MODULAR MEDICAL" OR THE "COMPANY"), AN INSULIN DELIVERY TECHNOLOGY COMPANY WITH THE FIRST FDA-CLEARED PATCH PUMP DESIGNED SPECIFICALLY TO TARGET ALL ADULT "ALMOST-PUMPERS" WITH ITS USER-FRIENDLY AND AFFORDABLE DESIGN, TODAY ANNOUNCED THAT IT HAS PRICED AN UNDERWRITTEN PUBLIC OFFERING (THE "OFFERING") OF 12,173,000 SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE 6,086,500 SHARES OF ITS COMMON STOCK. EACH TWO SHARES OF COMMON STOCK ARE BEING OFFERED AND SOLD TOGETHER WITH ONE ACCOMPANYING WARRANT AT A COMBINED OFFERING AT A PRICE OF $0.77, YIELDING AN EFFECTIVE PRICE OF $0.38 PER SHARE AND $0.01 PER WARRANT.

MODULAR MEDICAL ANNOUNCES PRICING OF $4.68 MILLION PUBLIC OFFERING

SAN DIEGO, CA / ACCESS NEWSWIRE / DECEMBER 9, 2025 / MODULAR MEDICAL, INC. (NASDAQ:MODD) ("MODULAR MEDICAL"), AN INSULIN DELIVERY TECHNOLOGY COMPANY WITH THE FIRST FDA-CLEARED PATCH PUMP DESIGNED SPECIFICALLY TO TARGET ALL ADULT "ALMOST-PUMPERS" WITH ITS USER-FRIENDLY AND AFFORDABLE DESIGN, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING (THE "OFFERING") OF SHARES OF ITS COMMON STOCK AND WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. THE SHARES OF THE COMMON STOCK AND THE ACCOMPANYING WARRANTS ARE IMMEDIATELY SEPARABLE AND WILL BE ISSUED SEPARATELY BUT CAN ONLY BE PURCHASED TOGETHER IN THIS OFFERING.

MODULAR MEDICAL ANNOUNCES PROPOSED PUBLIC OFFERING

STUDY TO DELIVER INSULIN TO INTERNAL TESTERS WEARING CONTINUOUS GLUCOSE MONITORS SAN DIEGO, CA / ACCESS NEWSWIRE / NOVEMBER 17, 2025 / MODULAR MEDICAL, INC. (NASDAQ:MODD) ("MODULAR MEDICAL" OR THE "COMPANY"), A LEADER IN INNOVATIVE INSULIN DELIVERY TECHNOLOGY TARGETING THE $3 BILLION ADULT "ALMOST-PUMPERS" DIABETES MARKET WITH USER-FRIENDLY, AFFORDABLE PATCH PUMPS, TODAY ANNOUNCED INSTITUTIONAL REVIEW BOARD ("IRB") APPROVAL TO CONDUCT AN IN-HOUSE STUDY OF ITS NEXT-GENERATION PIVOT INSULIN DELIVERY SYSTEM USING INSULIN ON PEOPLE WITH DIABETES (THE "STUDY"). PURSUANT TO U.S. FOOD AND DRUG ADMINISTRATION ("FDA") REGULATIONS, AN IRB IS A GROUP THAT HAS BEEN FORMALLY DESIGNATED TO REVIEW AND MONITOR BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS.

MODULAR MEDICAL RECEIVES IRB APPROVAL TO DELIVER INSULIN USING PIVOT PATCH PUMP

-TARGETS $3 BILLION "ALMOST-PUMPER" MARKET WITH FIRST SIMPLIFIED AND REMOVABLE/REPLACEABLE INSULIN PATCH PUMP - AIMS TO IMPROVE PATIENT AND CLINICIAN EXPERIENCE FOR THE CARE OF DIABETES SAN DIEGO, CA / ACCESS NEWSWIRE / NOVEMBER 14, 2025 / MODULAR MEDICAL, INC. (NASDAQ:MODD) ("MODULAR MEDICAL" OR THE "COMPANY") TODAY ANNOUNCED THE 510(K) PREMARKET SUBMISSION OF ITS NEXT GENERATION PIVOT TUBELESS PATCH PUMP TO THE U.S. FOOD AND DRUG ADMINISTRATION (THE "FDA"). THE COMPANY EXPECTS TO COMMENCE THE COMMERCIAL LAUNCH OF ITS PIVOT PUMP IN Q1 2026.

MODULAR MEDICAL SUBMITS PIVOT TUBELESS INSULIN PATCH PUMP FOR FDA 510(K) CLEARANCE

KEY HIGHLIGHTS: PIVOT CONTROLLER LINE VALIDATED: MANUFACTURING LINE HAS NOW BEEN VALIDATED FOR HUMAN-USE PRODUCTION IN SUPPORT OF EXPECTED Q1 2026 MARKET LAUNCH. PIVOT WILL BE FIRST TWO-PART TUBELESS PATCH PUMP: PIVOT, A 3 MILLILITER REMOVABLE PATCH PUMP, TARGETS THE $3 BILLION DOLLAR MARKET FOR ADULT "ALMOST-PUMPERS" WITH ITS AFFORDABLE, USER-FRIENDLY, EASY-TO-LEARN DESIGN.

MODULAR MEDICAL ANNOUNCES SUCCESSFUL VALIDATION OF CONTROLLER LINE FOR PIVOT INSULIN DELIVERY SYSTEM

KEY HIGHLIGHTS: PIVOT CONTINUES TO PROGRESS TOWARD CE MARK CERTIFICATION IN 2026 STAGE 1 ISO AUDIT COMPLETED WITH STAGE 2 PLANNED FOR 1H2026 SAN DIEGO, CA / ACCESS NEWSWIRE / OCTOBER 28, 2025 / MODULAR MEDICAL, INC. (NASDAQ:MODD) ("MODULAR MEDICAL" OR THE "COMPANY"), A LEADER IN INNOVATIVE INSULIN DELIVERY, TODAY ANNOUNCED THAT IT IS CONTINUING TO PROGRESS TOWARD CE MARK CERTIFICATION UNDER THE EUROPEAN UNION MEDICAL DEVICE REGULATION ("EU MDR 2017/745"). AS PART OF THIS PROCESS, THE COMPANY IS PLEASED TO ANNOUNCE THE SUCCESSFUL COMPLETION OF ITS STAGE 1 ISO 13485:2016 AUDIT, CONDUCTED BY BSI, ITS NOTIFIED BODY AND REGISTRAR.

MODULAR MEDICAL ANNOUNCES ONGOING PROGRESS TO OBTAIN CE MARK

-SEASONED EXECUTIVE WITH PROVEN TRACK RECORD IN INTERNATIONAL PUMP LAUNCHES TO ACCELERATE GLOBAL ADOPTION OF USER FRIENDLY, AFFORDABLE PATCH PUMPS SAN DIEGO, CA / ACCESS NEWSWIRE / OCTOBER 6, 2025 / MODULAR MEDICAL, INC. (NASDAQ:MODD) ("MODULAR MEDICAL" OR THE "COMPANY"), A LEADER IN INNOVATIVE INSULIN DELIVERY TECHNOLOGY TARGETING THE $3 BILLION ADULT "ALMOST-PUMPERS" DIABETES MARKET WITH EASY TO LEARN AND OPERATE USER-FRIENDLY, AFFORDABLE PATCH PUMPS, TODAY ANNOUNCED THE APPOINTMENT OF DAVID BOSSHARD AS HEAD OF INTERNATIONAL OPERATIONS. WITH TWO DECADES OF EXPERTISE IN SCALING SIMILAR TUBELESS INSULIN DELIVERY SYSTEMS ACROSS EUROPE AND BEYOND, MR.

MODULAR MEDICAL APPOINTS DAVID BOSSHARD TO LEAD ITS INTERNATIONAL EXPANSION FOR THE PIVOT INSULIN DELIVERY SYSTEM

SAN DIEGO, CA / ACCESS NEWSWIRE / SEPTEMBER 29, 2025 / MODULAR MEDICAL, INC. (NASDAQ:MODD) ("MODULAR MEDICAL" OR THE "COMPANY"), A LEADER IN INNOVATIVE INSULIN DELIVERY TECHNOLOGY TARGETING THE $3 BILLION ADULT "ALMOST-PUMPERS" DIABETES MARKET, TODAY ANNOUNCED THE EXERCISE OF CERTAIN EXISTING WARRANTS ISSUED IN MAY 2023 AND MARCH 2025 (THE "EXISTING WARRANTS") AT A REDUCED EXERCISE PRICE OF $0.68 PER SHARE. THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THE EXISTING WARRANTS ARE REGISTERED PURSUANT TO EFFECTIVE REGISTRATION STATEMENTS ON FORM S-1 (FILE NO.

MODULAR MEDICAL ANNOUNCES EXERCISE OF WARRANTS FOR $4.4 MILLION IN GROSS PROCEEDS

-MORE THAN 6,000 MODD1 CARTRIDGES PRODUCED - CONVERSION TO PIVOT-READY MANUFACTURING IN PREPARATION FOR PRODUCT LAUNCH IN 1Q26 SAN DIEGO, CA / ACCESS NEWSWIRE / AUGUST 26, 2025 / MODULAR MEDICAL, INC. (NASDAQ:MODD) ("MODULAR MEDICAL" OR THE "COMPANY"), AN INSULIN DELIVERY TECHNOLOGY COMPANY WITH THE FIRST FDA-CLEARED PATCH PUMP DESIGNED SPECIFICALLY TO TARGET ALL ADULT "ALMOST-PUMPERS" WITH ITS USER-FRIENDLY AND AFFORDABLE DESIGN, TODAY ANNOUNCED THAT THE MODD1 PRODUCT CARTRIDGE PRODUCTION RUN HAS BEEN COMPLETED AND ITS MANUFACTURING LINE IS BEING CONVERTED TO PRODUCTION FOR ITS PIVOT PRODUCT. "I WANT TO CONGRATULATE OUR OPERATIONAL TEAM FOR THE SUCCESSFUL VALIDATION OF OUR MODD1 MANUFACTURING PROCESS AND PRODUCTION OF HUMAN USE CARTRIDGES," SAID JEB BESSER, CEO OF MODULAR MEDICAL.

Modular Medical, Inc.

MODD

Price

Financial Reports

No items found.

Press Releases

Modular Medical, Inc.

MODD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MODD